The EMA has validated a Type II Variation marketing authorization application for T-DXd plus pertuzumab in first-line unresectable or metastatic HER2-positive breast cancer.

Click for more ➡️

The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd/pertuzumab in first-line HER2+ metastatic breast cancer.